Dose prescription and reporting in stereotactic body radiotherapy: A multi-institutional study

Das, Indra J.; Yadav, Poonam; Andersen, Aaron; Chen, Zhe Jay; Huang, Long; Langer, Márk; Lee, Choonik; Lin, Li; Popple, Richard A.; Rice, R.; Schiff, Peter B.; Zhu, Timothy C.; Abazeed, Mohamed E.

doi:10.1016/j.radonc.2023.109571

Cited by 4 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considerable heterogeneity among experienced SBRT centers regarding patient selection, prescription, and treatment delivery approaches was already noted by Karam et al in their review of SBRT practices for head and neck cancer [ 1 ]. However, this observation argues for standardization of dose prescription and reporting in SBRT for head and neck cancer to allow for more credible comparisons of treatment outcomes between different institutions [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Stereotactic Body Radiotherapy as a Curative Treatment for De Novo Mucosal Carcinoma of the Head and Neck: A Feasible Alternative Option for Fragile Patients with Small Lesion: A Systematic Review

Strojan,

Kokalj,

Plavc

et al. 2024

Cancers

View full text Add to dashboard Cite

Stereotactic body radiotherapy (SBRT) is characterized by a high dose per fraction, well-defined small targets, superior dose conformity, and a steep off-target dose gradient. A literature search was conducted to examine the experience with SBRT as a curative treatment for newly diagnosed mucosal carcinoma of the head and neck (MCHN). Four retrospective case series and one prospective phase I clinical trial published between 2012 and 2020 described 124 patients. SBRT was mainly performed in older patients with different tumor sites. The median size of the planning target volumes ranged from 5.3 to 41 cm3. Different approaches were used to create margins. In two studies, limited elective nodal irradiation was performed. The equivalent doses used were 60–83.33 Gy delivered in five fractions. Considerable heterogeneity was observed in the radiation dose specification. The incidence of grade ≥3 late toxicity was 0–8.3%, with local and regional control ranging from 73% to 100%. Improved or stable quality of life after SBRT was reported in two studies. Curative-intent SBRT for de novo MCHN appears to be an effective and relatively safe treatment for small tumor targets, preferably without concomitant elective tissue irradiation. Standardization of SBRT practice and well-designed prospective clinical trials are needed to better define the role of SBRT in this setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Stereotactic Body Radiotherapy as a Curative Treatment for De Novo Mucosal Carcinoma of the Head and Neck: A Feasible Alternative Option for Fragile Patients with Small Lesion: A Systematic Review

Strojan,

Kokalj,

Plavc

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Treatment planning and delivery practice of lung SBRT: Results of the 2022 ESTRO physics survey

Carver,

Scaggion,

Jurado-Bruggeman

et al. 2024

Radiotherapy and Oncology

View full text Add to dashboard Cite

Stereotactic Radiation Therapy Planning, Dose Prescription and Delivery in Veterinary Medicine: A Systematic Review on Completeness of Reporting and Proposed Reporting Items

Rohrer Bley,

Meier,

Turek

et al. 2024

Vet Comparative Oncology

View full text Add to dashboard Cite

Increasing numbers of dogs and cats with cancer are treated with stereotactic radiosurgery, stereotactic radiation therapy or stereotactic body radiotherapy (SRS, SRT or SBRT). We provide a systematic review of the current data landscape with a focus on technical and dosimetric data of stereotactic radiotherapy in veterinary oncology. Original peer‐reviewed articles on dogs and cats with cancer treated with SRT were included. The systematic search included Medline via PubMed and EMBASE. The study was performed according to the Preferred Reporting Items for Systematic Reviews (PRISMA) statement. We assessed the manuscripts regarding outcome reporting, treatment planning, dose prescription, ‐delivery and ‐reporting as well as quality assurance. As of February 2024, there are 80 peer‐reviewed publications on various disease entities on SRS, SRT and SBRT in veterinary medicine. Overall, we found often insufficient or highly variable technical data, with incomplete information to reproduce these treatments. While in some instances, technical factors may not impact clinical outcome, the variability found in protocols, outcome and toxicity assessments precludes accurate and reliable conclusions for a benefit of stereotactic radiotherapy for many of the treated diseases. In line with the extensive recommendations from human stereotactic radiotherapy practise, we propose a draft of reporting items for future stereotactic radiation treatments in veterinary medicine. SRS, SRT and SBRT have specific clinical and technological requirements that differ from those of standard radiation therapy. Therefore, a deep understanding of the methodologies, as well as the quality and precision of dose delivery, is essential for effective clinical knowledge transfer.

show abstract

Dose prescription and reporting in stereotactic body radiotherapy: A multi-institutional study

Cited by 4 publications

References 62 publications

Stereotactic Body Radiotherapy as a Curative Treatment for De Novo Mucosal Carcinoma of the Head and Neck: A Feasible Alternative Option for Fragile Patients with Small Lesion: A Systematic Review

Stereotactic Body Radiotherapy as a Curative Treatment for De Novo Mucosal Carcinoma of the Head and Neck: A Feasible Alternative Option for Fragile Patients with Small Lesion: A Systematic Review

Treatment planning and delivery practice of lung SBRT: Results of the 2022 ESTRO physics survey

Stereotactic Radiation Therapy Planning, Dose Prescription and Delivery in Veterinary Medicine: A Systematic Review on Completeness of Reporting and Proposed Reporting Items

Contact Info

Product

Resources

About